PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris:BIO), a Company dedicated to orphan oncology products and specialty products, today announces the initiation of ReLive, its phase III clinical trial with Livatag® (doxorubicin Transdrug™), as scheduled in the advancement calendar of the project. This international, multicenter, randomized phase III trial aims at evaluating the efficacy of Livatag® on overall survival in nearly 400 patients suffering from Hepato Cellular Carcinoma, resistant or intolerant to sorafenib.
